Management of Vaginal Bleeding After First Depo-Provera Injection
Initial Assessment and Treatment
- The Centers for Disease Control and Prevention recommends ruling out pregnancy, sexually transmitted infections (STIs), pathologic uterine conditions, and medication interactions before initiating treatment for vaginal bleeding after the first Depo-Provera injection 1, 2
- The American College of Obstetricians and Gynecologists suggests testing for chlamydia and gonorrhea in patients with irregular bleeding patterns 1, 2
Understanding the Bleeding Pattern and Treatment Approach
- The World Health Organization notes that unscheduled spotting or light bleeding is extremely common with DMPA use, particularly in the first few months, and generally decreases with continued use 1
- The Centers for Disease Control and Prevention recommends providing reassurance and counseling that irregular bleeding is a normal, expected side effect, and no medical treatment is required unless the patient requests it 1, 2
- For patients who desire treatment, the American College of Obstetricians and Gynecologists suggests using NSAIDs, such as mefenamic acid 500 mg three times daily for 5-7 days, to reduce bleeding 1, 2
Critical Counseling Points
- The Centers for Disease Control and Prevention emphasizes that irregular bleeding is not harmful and does not indicate contraceptive failure, and that bleeding patterns typically improve with continued use 1, 2
- The American College of Obstetricians and Gynecologists recommends counseling patients that amenorrhea becomes increasingly common and is also not harmful, and that contraceptive efficacy remains intact provided injections are given on schedule 1, 2
What NOT to Do
- The American College of Obstetricians and Gynecologists advises against performing unscheduled cervical cancer screening outside the regular screening program for vaginal bleeding alone 3
- The Centers for Disease Control and Prevention recommends not assuming that bleeding indicates contraceptive failure or reduced efficacy, and not discontinuing the method prematurely without adequate counseling about expected bleeding patterns 1, 2